期刊文献+

急诊PCI联合替罗非班治疗急性心肌梗死患者的有效性和安全性研究 被引量:6

Emergency Medical Treatment PCI Treats the Acute Myocardial Infarction Patient's Validity and the Security Jointly for Tirofiban Study
原文传递
导出
摘要 目的探讨急性前壁或下壁心肌梗死患者急诊经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)早期联合应用替罗非班的临床疗效及安全性。方法我院2008年2月至2010年6月心内科住院治疗的急性前壁或下壁心肌梗死患者50例,随机分为替罗非班组(n=26)和对照组(n=24),替罗非班组在介入术前常规给予阿司匹林、氯吡格雷、辛伐他汀等治疗,同时静脉给予盐酸替罗非班,以输液泵持续泵入;对照组除未加盐酸替罗非班外,其他治疗同替罗非班组。观察两组术中再灌注血管终末段显影祯数和术后90 min内ST段回落情况、肌酸激酶同工酶(CK-MB)酶峰时间,术中及术后重要脏器出血情况、心衰发生率、术后1周心功能情况。结果两组靶血管PCI成功率均达100%,术中及术后出血事件、心衰、病死率无统计学差异;替罗非班组术中再灌注血管终末段显影祯数和术后90 min内ST段回落情况均优于对照组(P<0.05),术后替罗非班组CK-MB酶峰时间较对照组提前(P<0.05);1周后心脏彩超评价心脏左室射血分数(LVEF)无统计学差异。结论急性前壁或下壁心肌梗死患者急诊PCI联合应用替罗非班安全、有效,能改善冠脉微循环及心肌灌注。 目的探讨急性前壁或下壁心肌梗死患者急诊经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)早期联合应用替罗非班的临床疗效及安全性。方法我院2008年2月至2010年6月心内科住院治疗的急性前壁或下壁心肌梗死患者50例,随机分为替罗非班组(n=26)和对照组(n=24),替罗非班组在介入术前常规给予阿司匹林、氯吡格雷、辛伐他汀等治疗,同时静脉给予盐酸替罗非班,以输液泵持续泵入;对照组除未加盐酸替罗非班外,其他治疗同替罗非班组。观察两组术中再灌注血管终末段显影祯数和术后90 min内ST段回落情况、肌酸激酶同工酶(CK-MB)酶峰时间,术中及术后重要脏器出血情况、心衰发生率、术后1周心功能情况。结果两组靶血管PCI成功率均达100%,术中及术后出血事件、心衰、病死率无统计学差异;替罗非班组术中再灌注血管终末段显影祯数和术后90 min内ST段回落情况均优于对照组(P&lt;0.05),术后替罗非班组CK-MB酶峰时间较对照组提前(P&lt;0.05);1周后心脏彩超评价心脏左室射血分数(LVEF)无统计学差异。结论急性前壁或下壁心肌梗死患者急诊PCI联合应用替罗非班安全、有效,能改善冠脉微循环及心肌灌注。
出处 《中国现代应用药学》 CAS CSCD 北大核心 2011年第S1期1375-1379,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 替罗非班 急性心肌梗死 经皮冠状动脉介入治疗 tirofiban acute myocardial infarction percutaneous coronary intervention
  • 相关文献

参考文献9

  • 1黄静涵,陈纪林,杨跃进,乔树宾,姚民,秦学文,徐波,刘海波,吴永建,高润霖.1404例冠心病合并与不合并2型糖尿病患者冠状动脉造影特点对照分析[J].临床医学,2007,27(11):17-18. 被引量:22
  • 2叶飞,陈绍良,朱中生,张俊杰,林松,周陵,刘玲玲,阚静,段宝祥.老年高危急性冠状动脉综合征患者介入术中应用替罗非班的有效性和安全性[J].中国介入心脏病学杂志,2007,15(2):93-95. 被引量:16
  • 3Keeley EC,Boura JA,Grines CL,et al.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet,The . 2003
  • 4Bolognese L,Falsini G,Liistro F,et al.Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. Journal of the American College of Cardiology . 2006
  • 5Feldman L J,Coste P,Furber A,et al.Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation . 2003
  • 6Henriques J P,Zijlstra F,Ottervanger J P,et al.Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. European Heart Journal . 2002
  • 7The RESTORE Investigators.Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation . 1997
  • 8Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction. Journal of the American College of Cardiology . 2007
  • 9Valgimigli M,Percoco G,Barbieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. Journal of the American College of Cardiology . 2004

二级参考文献18

  • 1de Feyler PJ,van den Brand M,Jaacman G,et al.Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty.Circulation,1991.83:927-936.
  • 2Lincoff AM,Popma JJ,Ellis SG,et al.Abrupt vessel closure complicating coronary angioplasty:Clinical,angiographic and therapeutic profile.J Am Coll Cardiol,1992,19:926-935.
  • 3The EPIC investigators.Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in hish-risk coronary angioplasty.N Engl J Med,1994,330:956-961.
  • 4Sekiguchi M,Hoshizaki H,Adachi H,et al.Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting:A randomized comparison of ticlopidine and cilostazol.Cire J.2004.68:610-614.
  • 5Blankenship JC.Bleeding complications of glycoprotein Ⅱb/Ⅲa receptor inhibitors.Am Heart J,1999,138(4Pt2):287-296.
  • 6Elliott MA,Marc C,Peter JLMB,et al.The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI:A Method for Prognostication and Therapeutic Decision Making.JAMA,2000,284:835-842.
  • 7The platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM·PLUS)trial investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,38:1488-1497.
  • 8The platelet receptor inhibition for ischemic syndrome management(PRISM)study investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Engl J Med,1998,338:1498-1505.
  • 9ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction.A report of the American College of Cardiology/Ameri can Heart Association task force on practice guidelines(committee on the management of patients with unstable angina).J·Am Coll Cardiol.2002.40:1366-1374.
  • 10The RESTORE investigators.Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1445-1453.

共引文献36

同被引文献51

  • 1宋玉娥,王琳,李芳,龚培力,王朝晖,党瑜华.盐酸替罗非班对急性冠状动脉综合征的疗效和安全性评价[J].临床心血管病杂志,2006,22(4):220-222. 被引量:71
  • 2陈晖,贾三庆,严松彪,王雷,李虹伟,苏淑红,高红丽,王璐,韩炜,沈潞华.急性心肌梗死患者经皮冠脉介入治疗肌酐水平对预后的影响[J].介入放射学杂志,2006,15(4):198-201. 被引量:5
  • 3郭来敬,唐强,胡大一.国产盐酸替罗非班在急诊经皮冠状动脉介入治疗中临床应用的研究[J].临床荟萃,2006,21(23):1697-1700. 被引量:15
  • 4Haitert H. Thrombelastography. A method for physical analysis ofblood coagulation[J]. Z Gesamte Exp Med,1951,117(2):189-203.
  • 5Miller BE, Tosone SR, GuzzeRa NA, et al. Fibrinogen in childrenundergoing cardiac surgery:is it effective?[J]. Anesth Analg,2004,99(5):1341-1346.
  • 6Tanaka KA, Szlam F, Sun HY, et al. Thrombin Generation Assay andViscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfraetionated Heparin andBivalirudin[J]. Anesth Analg,2007,105:933.
  • 7Chen A, Teraya J. Global hemostasis testing thromboelastogra-phy:old technology, new applications[J]. Clin Lab Med,2009,29(2):391-407.
  • 8Guibel PA, Bliden KP, Samara W,et al. Clopidogrel effect onplate-let reactivity in patients with stent thrombosis:results of theCREST Study[J]. J Am Coll Cardiol,2005,46:1827-1832.
  • 9Bliden Kp, DiChiara J, Tantry Us, et al. Increased risk in patients withhigh platelet aggregation receiving chronic clopidogrel therapyundergoing percutaneous coronary intervention:is the currentantiplatelet therapy adequate? [J]. J Am Con Cardiol,2007,3,49(6):657-666.
  • 10Matetzky S, Shenkman B,Guetta V, et al. Clopidogrel resistance isassociated with increased risk of recurrent atherothrombotic events inpatients with acute myocardial infarction [J]. Circulation,2004,109:3171-3175.

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部